The personalized drug will tackle a patient’s stage three melanoma, with results expected in the coming months A Russian melanoma patient has received the first personalized cancer vaccine in what is hoped to be a breakthrough in the treatment of the disease, the Russian Health Ministry said in a statement to TASS on Wednesday. Last year, the ministry approved two domestically-made medicines: Neooncovac, an mRNA-based vaccine for advanced melanoma, and Oncopept, a peptide treatment targeting